**About the Editors**

**Susan Costantini** graduated in Chemistry and achieved the Specialty Certification in Clinical Pathology and Biochemistry at University Federico II of Naples (Italy). She obtained her PhD in Computational Biology at the Second University of Naples and Master's degree in Environment and Cancer at the University of Sannio. She is a contract professor of Biology, Biochemistry, and Bioinformatics at University Federico II of Naples and Vanvitelli Campania. Since 2008, she has been a researcher at the Mercogliano Laboratory of the National Cancer Institute of Naples "Pascale Foundation". She is the author of more than 140 publications (Scopus H-index: 31). Her research activity is currently focused on the study of the cytokinomic and metabolomic/lipidic profile by 1H-NMR in various cellular systems, biological fluids, and tissues of cancer patients. Moreover, her research activities include the application of systems biology approaches to integrate "omics" data by computational and bioinformatics methods.

**Alfredo Budillon** graduated in Medicine and achieved the Specialty Certification in Oncology at University Federico II, Naples, Italy. He obtained his PhD in Oncology from University G. D'Annunzio of Chieti, Italy, and Master's degree in Health Economy, Management, and Bioethics. He gained experience in biochemistry and antitumor experimental therapeutics as a post-doc during a stage fellowship at the National Cancer Institute, Bethesda, USA. Dr. Budillon is currently the chief of the Experimental Pharmacology Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy. He is the author of more than 170 publications (Scopus H-index: 45). His research interest is focused on the molecular mechanism of novel anticancer drugs and the potential combination approaches between conventional and targeted-based drugs, particularly epigenetic drugs. His other scientific interests are related to cancer-associated extracellular vesicles as well as proteomics/metabolomics approaches in defining new molecular diagnostic/prognostic biomarkers and therapeutic targets.
